NV3P Stock Overview
A clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NanoViricides, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.22 |
| 52 Week High | US$3.02 |
| 52 Week Low | US$0.90 |
| Beta | 0.97 |
| 11 Month Change | -9.63% |
| 3 Month Change | -29.07% |
| 1 Year Change | 34.81% |
| 33 Year Change | -70.10% |
| 5 Year Change | n/a |
| Change since IPO | -97.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| NV3P | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.6% | 0.8% | 0.8% |
| 1Y | 34.8% | -18.3% | 8.6% |
Return vs Industry: NV3P exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: NV3P exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| NV3P volatility | |
|---|---|
| NV3P Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NV3P's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NV3P's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 7 | Anil Diwan | www.nanoviricides.com |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
NanoViricides, Inc. Fundamentals Summary
| NV3P fundamental statistics | |
|---|---|
| Market cap | €19.05m |
| Earnings (TTM) | -€9.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs NV3P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NV3P income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.45m |
| Earnings | -US$9.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NV3P perform over the long term?
See historical performance and comparison